How to Export CBD to Europe: Novel Food Compliance 2026
To export CBD products from the United States into European Union markets in 2026, your brand must secure Novel Food authorization through the European Food Safety Authority (EFSA). This requires submitting a formal dossier containing toxicology studies, stability data, detailed manufacturing specs, and safety assessments — a process that costs $300,000–$500,000+ and typically takes 18–24 months from submission to decision.
Why CBD Is Classified as a Novel Food in the EU
The European Commission formally confirmed in January 2019 that CBD extracts, including hemp-derived ones, fall under the EU Novel Food Regulation (EU 2015/2283). The reasoning is straightforward: CBD was not consumed to a significant degree within the EU before May 15, 1997, the cut-off date for Novel Food classification.
What "Novel Food" Actually Means
A Novel Food is any food or food ingredient that lacks a significant history of consumption within the EU prior to 1997. It doesn't mean the product is dangerous — just that it hasn't been eaten long enough in Europe for regulators to consider it traditionally safe. Cold-pressed hempseed oil and hemp seeds themselves are exempt because they have that consumption history. CBD extracts do not.
The 2020 CJEU Ruling That Changed Everything
In November 2020, the Court of Justice of the European Union ruled in the Kanavape case (C-663/18) that CBD extracted from the whole Cannabis sativa plant is not a narcotic under the 1961 UN Single Convention. This landmark decision confirmed that EU member states cannot ban CBD products outright, opening the door for legal market entry — but only through the Novel Food pathway.
That ruling eliminated a major roadblock. Before it, some EU countries treated CBD as a controlled substance regardless of THC content. Now, the pathway is bureaucratic rather than prohibitive.
The EFSA Novel Food Application Process: Step by Step
This is where most American hemp brands underestimate the complexity. The EFSA process is not a simple registration — it's a full scientific authorization requiring original research data.
Step 1: Assemble Your Dossier
Your application dossier must follow EFSA's structured format and include nine core components:
- Identity of the Novel Food — full chemical characterization of your CBD product, including cannabinoid profile, terpene content, and manufacturing specifications
- Production process — detailed description from raw hemp biomass through extraction, winterization, distillation, and final formulation
- Compositional data — batch-to-batch consistency across at least three production runs, with third-party lab verification
- Specifications — proposed limits for CBD content, residual THC (must be below 0.2% in the finished product for most EU markets), heavy metals, pesticides, and microbial contaminants
- Stability data — shelf-life studies under accelerated and real-time storage conditions, typically covering 12–24 months
- Toxicological data — this is the expensive part (detailed below)
- Absorption, distribution, metabolism, and excretion (ADME) studies
- Nutritional information — if applicable to the product format
- Proposed uses and use levels — including target population groups and maximum daily intake recommendations
Step 2: Complete Required Toxicology Studies
The toxicology package is the single most expensive and time-consuming element. EFSA requires, at minimum:
- 90-day repeated dose oral toxicity study (OECD Test Guideline 408) — typically conducted in rats, costs $150,000–$250,000 alone
- Genotoxicity battery — including bacterial reverse mutation (Ames test), in vitro mammalian cell micronucleus test, and potentially an in vivo follow-up
- ADME/pharmacokinetic study — demonstrating how CBD is metabolized in the body
- Reproductive and developmental toxicity data — may be required depending on intended use levels
A 2022 analysis by the European Industrial Hemp Association (EIHA) estimated total toxicology costs at €250,000–€400,000 per application, with studies alone requiring 12–18 months to complete before you even submit.
Step 3: Submit Through the European Commission's E-Submission Portal
Applications go to the European Commission first, which performs a validity check before forwarding to EFSA for scientific assessment. The Commission checks that your dossier is administratively complete — missing a single section means rejection before EFSA even sees it.
Step 4: EFSA Scientific Assessment
Once EFSA accepts the dossier, their NDA Panel (Nutrition, Novel Foods, and Food Allergens) evaluates the science. EFSA publishes a scientific opinion, which takes roughly 9 months from acceptance — though clock-stops for additional data requests can extend this significantly.
As of early 2026, EFSA has not yet issued a final positive opinion on any standalone CBD Novel Food application. Several applications from EIHA member companies and individual brands are in the pipeline, with decisions expected throughout 2026.
Step 5: European Commission Authorization
If EFSA issues a favorable opinion, the European Commission drafts an implementing regulation to authorize the Novel Food. This involves a vote by EU member states through the Standing Committee on Plants, Animals, Food and Feed (SCoPAFF). Authorization applies EU-wide — you don't need separate approval from each member state.
Practical Export Requirements for US Hemp Brands
Beyond Novel Food authorization, American companies face additional hurdles when physically exporting CBD products into the EU.
THC Limits and Product Specifications
The EU's THC threshold for hemp-derived products is stricter than the US federal 0.3% delta-9 limit. Most EU member states require finished products to contain no more than 0.2% THC, though the EU raised the agricultural hemp cultivation threshold to 0.3% in 2023 under the reformed Common Agricultural Policy. For full-spectrum CBD products, this means your extraction and formulation process must be tightly controlled to stay under 0.2% in the final consumer product.
| Requirement | United States (2018 Farm Bill) | European Union (2026) |
|---|---|---|
| THC limit (agricultural hemp) | ≤0.3% delta-9 THC | ≤0.3% THC (since 2023 CAP reform) |
| THC limit (finished products) | ≤0.3% delta-9 THC | ≤0.2% THC (most member states) |
| Pre-market authorization | Not required for hemp supplements | Novel Food authorization required |
| Regulatory body | FDA (limited enforcement) | EFSA + European Commission |
| Estimated approval cost | N/A | $300,000–$500,000+ |
| Typical timeline | Immediate market entry | 18–24 months after submission |
Customs and Import Documentation
Every CBD shipment entering the EU must include:
- Certificate of Analysis (COA) from an ISO/IEC 17025–accredited laboratory confirming cannabinoid content, heavy metals, pesticide residues, and microbiological safety
- Phytosanitary certificate if shipping raw or minimally processed hemp material
- TRACES (Trade Control and Expert System) notification for products of plant origin entering the EU
- Proper HS (Harmonized System) tariff classification — CBD oils typically fall under HS code 1302.19 (vegetable saps and extracts) or 2106.90 (food preparations not elsewhere specified), depending on formulation
Misclassification at customs is a common and costly mistake. One wrong code can result in seizure, destruction of goods, or reclassification as a pharmaceutical — which triggers an entirely different regulatory framework under the European Medicines Agency.
Labeling and Claims Compliance
EU food labeling rules (Regulation EU 1169/2011) are significantly more prescriptive than US requirements. Your labels must include:
- Ingredient list in the language of the destination country
- Net quantity in metric units
- Allergen declarations
- Nutritional information per 100g and per serving
- Batch/lot number for traceability
- No health claims unless specifically authorized under the EU Nutrition and Health Claims Regulation (EC 1924/2006)
That last point catches many American brands off guard. Claims like "reduces anxiety" or "supports sleep" that might slide in the US supplement market are strictly prohibited in the EU without authorized health claim approval — a separate, equally demanding process.
Cost-Benefit Analysis: Is EU Market Entry Worth It for Your Brand?
The European CBD market was valued at approximately €2.6 billion in 2023 according to the Brightfield Group, with Germany, the UK (separate from the EU post-Brexit), France, and the Netherlands representing the largest national markets.
Consortium Applications: Splitting the Cost
Several industry groups, most notably EIHA, are pursuing consortium-based Novel Food applications. The idea is simple: multiple companies share the cost of generating toxicology and safety data for a standardized CBD extract specification. If your product falls within that specification, you can reference the consortium's data rather than generating your own.
This approach can reduce per-company costs to $50,000–$100,000 in consortium fees rather than the full $300,000–$500,000 for a standalone application. The trade-off is less control over timelines and product specifications.
The "Enforcement Gap" Reality
Here's what nobody wants to put in writing but every industry participant knows: thousands of CBD products are currently sold across EU member states without Novel Food authorization. Enforcement varies dramatically by country. Germany's Federal Office of Consumer Protection actively pursues unauthorized products. The Netherlands takes a similarly strict approach. Italy and Spain have historically been more lenient, though enforcement is tightening.
Selling without authorization is a business risk, not a legal gray area. It's unambiguously illegal under EU food law. Enforcement simply hasn't caught up with market reality — yet. As EFSA issues its first authorizations in 2026, expect enforcement to ramp up significantly against unauthorized competitors.
For brands building wholesale distribution networks, compliance from day one positions you as a reliable supplier when enforcement narrows the competitive field.
Key Takeaways
- CBD products require Novel Food authorization under EFSA before they can be legally sold as food or supplements in the EU — there is no shortcut or registration-only pathway.
- Total cost for a standalone application runs $300,000–$500,000+, with toxicology studies alone accounting for $150,000–$250,000. Consortium applications through EIHA can significantly reduce individual costs.
- The process takes 18–24 months minimum from dossier submission to authorization, not counting the 12–18 months needed to generate toxicology data beforehand.
- EU THC limits for finished products (0.2%) are stricter than the US Farm Bill threshold — formulation adjustments may be necessary for full-spectrum products.
- No health claims are permitted on CBD products in the EU without separate authorization under EC 1924/2006.
- 2026 is a pivotal year — the first EFSA positive opinions on CBD are expected, which will simultaneously legitimize compliant brands and trigger enforcement against unauthorized sellers.
These statements have not been evaluated by the FDA. CBD products are not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare provider and qualified regulatory counsel before pursuing EU market entry.
Frequently Asked Questions
Q: What is the EFSA Novel Food process for CBD products? A: EFSA's Novel Food process requires submitting a comprehensive scientific dossier containing toxicology studies, manufacturing specifications, stability data, and proposed use levels. EFSA's NDA Panel conducts a scientific risk assessment, publishes an opinion, and if favorable, the European Commission authorizes the product for EU-wide sale. The process typically takes 18–24 months from accepted submission to final decision.
Q: How much does EU Novel Food authorization for CBD cost? A: A standalone Novel Food application for CBD costs approximately $300,000–$500,000, with toxicology studies representing the largest expense at $150,000–$250,000. Joining a consortium application through organizations like EIHA can reduce individual costs to $50,000–$100,000, though you'll have less control over the product specification and timeline.
Q: Is it legal to sell CBD products in the EU without Novel Food authorization? A: No. Selling CBD as a food or food supplement without Novel Food authorization violates EU Regulation 2015/2283. While enforcement varies by member state — Germany and the Netherlands enforce strictly, while some southern European countries have been more lenient — unauthorized sale is unambiguously illegal and subject to product seizure, fines, and market withdrawal orders.
Q: What THC limit applies to CBD products exported to the EU? A: Most EU member states require finished consumer products to contain no more than 0.2% total THC. This is stricter than the US federal 0.3% delta-9 THC limit under the 2018 Farm Bill. While the EU raised its agricultural hemp cultivation threshold to 0.3% in 2023, the finished product limit remains 0.2% in most jurisdictions.
Q: Does the UK follow the same CBD Novel Food process as the EU? A: No. Since Brexit, the UK operates its own Novel Food pathway through the Food Standards Agency (FSA), which is separate from EFSA. The UK FSA has its own validated list of CBD products, different timelines, and distinct data requirements. EU Novel Food authorization does not grant automatic access to the UK market, and vice versa.
Q: Can US hemp brands use existing American lab data for EU Novel Food submissions? A: Partially. EFSA accepts toxicology studies conducted at international labs following OECD test guidelines and GLP (Good Laboratory Practice) standards, regardless of geographic location. However, the specific study designs, endpoints, and reporting formats must meet EFSA's requirements — which may differ from FDA expectations. COA data from ISO/IEC 17025–accredited US labs is generally accepted for compositional analysis.
Q: What happens after the first EU Novel Food authorizations for CBD are granted? A: Once EFSA issues positive opinions and the European Commission authorizes specific CBD products, two things happen simultaneously: authorized brands gain legal market access across all 27 EU member states, and enforcement against unauthorized products is expected to intensify. Early movers with authorization will hold a significant competitive advantage as non-compliant products are removed from shelves.
About the Author — Hurcann Editorial Team The Hurcann team has spent years working directly with licensed hemp cultivators, extraction labs, and independent testing facilities across the United States. Our content is reviewed against current COA data, state hemp regulations, and peer-reviewed cannabinoid research before publication. We are not medical professionals and nothing here constitutes medical advice — always consult a healthcare provider before adding hemp products to your wellness routine.